Summary
IBSA UK has launched Hyaluxelle®, a breakthrough non-hormonal injectable treatment specifically designed to address vulvovaginal symptoms associated with menopause. Business Manchester reports this significant development in women's healthcare, representing a major advancement in treatment options for menopausal women. The introduction of this innovative therapy is particularly relevant to Greater Manchester's growing pharmaceutical and healthcare sector, potentially benefiting thousands of women across the region whilst reinforcing the area's position as a key hub for medical innovation.
Read the full story at Business Manchester
This is a summary written for the Manchester Business Services register. The full article belongs to Business Manchester — read it at source.
Organisations mentioned
- IBSA UK, Business Manchester
Common questions
- What is this article about?
- IBSA UK launches Hyaluxelle®, a non-hormonal injectable treatment for menopausal symptoms, marking a significant healthcare advancement for Greater Manchester's pharmaceutical sector.
- When was this published?
- This article was published on 3 February 2026.
- Who published this article?
- This article was published by Business Manchester, written by News Desk.
- Which organisations does this article mention?
- This article mentions IBSA UK, Business Manchester.